Text Size

A comparative study of a preservative-free latanoprost cationic emulsion (catioprost) and a BAK-preserved latanoprost solution in animal models

Daull P., Buggage R., Lambert G., Faure M.-O., Serle J., Wang R.-F., Garrigue J.-S.


  • 2012
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Pharmacology

  • Categories

    Preclinical development

  • Affiliations

    Novagali Pharma, Bâtiment Genavenir IV, 1, rue Pierre Fontaine, Evry cedex, F-91058, France; Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY, United States

Related Publications

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Esaki Y., Katsuta O., Kamio H., Noto T., Mano H., Iwamura R., Yoneda K., Odani-Kawabata N., Morishima K., Shams N.K.


In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models

Liang H., Baudouin C., Daull P., Garrigue J.-S., Buggage R., Brignole-Baudouin F.


The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo

Pellinen P., Huhtala A., Tolonen A., Lokkila J., Mäenpää J., Uusitalo H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022